Hybrid economic model in Iran: sanctions, military power, and structural evolution scenarios
Revista de Estudios Internacionales Mediterráneos · 29.06.2026 · (40) · 49-83
DOI: 10.15366/reim2026.40.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista de Estudios Internacionales Mediterráneos, online erschienen am 29.06.2026. Verfasst von Rouhollah Iran Shahy und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Iran’s economy is at a critical juncture, marked by structural imbalances such as persistent inflation, youth unemployment, and inequality, further exacerbated by international sanctions, diplomatic isolation, and armed conflict. This study integrates macroeconomic indicators with comparative political economy approaches, applying Rodrik’s (2007) framework on institutions and growth and Khan’s (2010) theory of political settlements to model three prospective scenarios. Sanctions have intensified poverty, labor precarity, and informal power structures. The IRGC has consolidated economic dominance, undermining institutional transparency. A hybrid governance model has emerged that sustains regime resilience but appears to accentuate its structural fragility.
Zitieren
APA
Shahy, R. I., & Hernández, S. B. (2026). Hybrid economic model in Iran: sanctions, military power, and structural evolution scenarios. Revista de Estudios Internacionales Mediterráneos, 49-83. https://doi.org/10.15366/reim2026.40.003
Vancouver
Shahy RI, Hernández SB. Hybrid economic model in Iran: sanctions, military power, and structural evolution scenarios. Revista de Estudios Internacionales Mediterráneos. 2026:49-83. doi:10.15366/reim2026.40.003
BibTeX
@article{Shahy2026,
author = {Shahy, Rouhollah Iran and Hernández, Sonia Benito},
title = {Hybrid economic model in Iran: sanctions, military power, and structural evolution scenarios},
journal = {Revista de Estudios Internacionales Mediterráneos},
year = {2026},
number = {40},
pages = {49--83},
doi = {10.15366/reim2026.40.003}
}
EUVIMED